377 related articles for article (PubMed ID: 29145556)
21. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
22. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
[No Abstract] [Full Text] [Related]
23. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
Gambichler T; Stockfleth E; Susok L
J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
[TBL] [Abstract][Full Text] [Related]
24. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
25. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
26. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
[TBL] [Abstract][Full Text] [Related]
27. Enteritis with immune checkpoint inhibitor use.
Sanders D; Webber D; Chatur N
CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
[No Abstract] [Full Text] [Related]
28. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
[No Abstract] [Full Text] [Related]
29. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
30. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
Meti N; Petrogiannis-Haliotis T; Esfahani K
J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
[No Abstract] [Full Text] [Related]
31. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
32. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland.
Dolaghan MJ; Oladipo B; Cooke CA; McAvoy CE
Eye (Lond); 2019 Oct; 33(10):1670-1672. PubMed ID: 31114029
[No Abstract] [Full Text] [Related]
33. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
34. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
35. Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use.
Muhailan M; Al-Shbool G
Am J Med Sci; 2020 Jan; 359(1):e1-e2. PubMed ID: 31395282
[No Abstract] [Full Text] [Related]
36. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
38. Uncommon esophagitis associated with nivolumab and ipilimumab therapy.
Inoue G; Utsumi T; Yoshizawa A
Dig Endosc; 2021 Mar; 33(3):467-468. PubMed ID: 33251627
[No Abstract] [Full Text] [Related]
39. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
40. Erythema Nodosum as the Initial Presentation of Nivolumab-Induced Sarcoidosis-Like Reaction.
Laroche A; Alarcon Chinchilla E; Bourgeault E; Doré MA
J Cutan Med Surg; 2018; 22(6):627-629. PubMed ID: 29772919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
